Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alfred Saleh"'
Autor:
Shannon Swift, RN, BSN, Osório Lopes Abath Neto, MD, Mohammad Hadi Bagheri, MD, Alfred Saleh, MD, Patrick J. Loehrer, Sr., MD, Arun Rajan, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100039- (2020)
Externí odkaz:
https://doaj.org/article/1236169765694bf7bbd09a4010def54e
Autor:
Alfred Saleh, Shannon Swift, Mohammad Hadi Bagheri, Arun Rajan, Patrick J. Loehrer, Osorio Abath Neto
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100039-(2020)
JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100039-(2020)
Autor:
Thomas A. Rado, Danjie Zhang, Wen Shi, Derek Nay, Andrei R. Shustov, Thomas A. Giever, Leonard M. Klein, Alfred Saleh, Jeffrey P. Sharman, Kathryn S. Kolibaba, Andres Forero, Sarit Assouline
Publikováno v:
Blood. 128:2963-2963
Introduction: Entospletinib (GS-9973) is an orally bioavailable, selective inhibitor of spleen tyrosine kinase (Syk). Syk is a mediator of B-cell receptor signaling in normal and transformed B-cells. Targeting the B-cell receptor (BCR)-signaling path
Autor:
Amanda F. Cashen, Sonali M. Smith, Nathan Fowler, Jeffrey Matous, Alfred Saleh, Peter Rosen, Samuel A. Jacobs, Sudha Parasuraman, Hongliang Shi, Peter P. Lee, Bipinkumar Amin, Michael E. Williams, Bruce D. Cheson, Jeffrey Letzer, Brad S. Kahl
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(25)
Purpose The aims of this multicenter study were to evaluate the response rate, progression-free survival, and toxicity of the combination of bortezomib, bendamustine, and rituximab in patients with follicular lymphoma whose disease was relapsed or re
Autor:
Bipinkumar Amin, Hongliang Shi, Jeffrey Letzer, Samuel A. Jacobs, Peter Rosen, Brad S. Kahl, Alfred Saleh, Jeffrey Matous, Bruce D. Cheson, Maureen Ross, Michael D. Williams, Amanda F. Cashen, Sonali M. Smith, Sudha Parasuraman, Nathan Fowler
Publikováno v:
Blood. 114:933-933
Abstract 933 Follicular lymphoma (FL) is an incurable, indolent B-cell non-Hodgkin lymphoma. Although survival has improved with the introduction of rituximab (Rituxan®, R), relapse is inevitable and new therapies are needed. Bortezomib (Velcade®,
Autor:
Jane E. Huang, Virginia K. Langmuir, Fan Zhang, J. Thomas Lee, Alfred Saleh, John D. Hainsworth
Publikováno v:
Blood. 104:4616-4616
Background: This study was designed to investigate the activity, safety, and pharmacokinetics of rituximab (Rituxan®, R) plus CHOP induction therapy followed by maintenance R in previously untreated patients with aggressive NHL. The initial results